ijms-logo

Journal Browser

Journal Browser

Orphan GPCRs: An Untapped Resource for Novel Drug Targets

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 3471

Special Issue Editors


E-Mail Website
Guest Editor
Department of Cancer Physiology, Moffitt Cancer Center, Tampa, FL 33612, USA
Interests: G protein coupled receptors (GPCRs); cell signaling; molecular pharmacology; drug discovery; target identification and validation; HTS; lead identification; metabolic disorders; cancer

E-Mail
Guest Editor
Moffitt Cancer Center, Tampa, FL, USA
Interests: GPCR focused drug Discovery

E-Mail
Guest Editor
University of Maryland, MD, USA
Interests: orphan/adhesion GPCR activation and signaling

Special Issue Information

Dear Colleagues,

The G-protein-coupled receptor (GPCR) superfamily is the largest and most diverse transmembrane protein family in the genome, with over 800 members identified to date. Of the ~360 druggable GPCRs, ~240 are classified as known receptors and are activated by ~70 known ligands, while ~120 are described as ‘orphan’ receptors (oGPCRs) whose endogenous ligands remain to be identified. The diversity of physiological responses that GPCRs regulate as well as the relative success in developing clinically active small molecule ligands for these receptors have made GPCRs the most successful drug target class. While 30–40% of currently marketed drugs target GPCRs, they target <10% of the superfamily; thus, the therapeutic potential of GPCRs is far from exhausted. Hence, oGPCRs represent the next generation of GPCR-focused drug targets for pharmaceutical intervention in a variety of diseases. This Special Issue will highlight oGPCR signaling, biology, and their physiological and therapeutic relevance.

Dr. Patricia H. McDonald
Dr. Ainhoa Nieto
Dr. Nariman Balenga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • GPCR
  • orphan GPCR
  • drug discovery
  • physiological and therapeutic relevance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2035 KiB  
Article
Genetic Deletion of Trace-Amine Associated Receptor 9 (TAAR9) in Rats Leads to Decreased Blood Cholesterol Levels
by Ramilya Z. Murtazina, Ilya S. Zhukov, Olga M. Korenkova, Elena A. Popova, Savelii R. Kuvarzin, Evgeniya V. Efimova, Larisa G. Kubarskaya, Ekaterina G. Batotsyrenova, Ekaterina A. Zolotoverkhaya, Anastasia N. Vaganova, Sergey A. Apryatin, Natalia V. Alenina and Raul R. Gainetdinov
Int. J. Mol. Sci. 2021, 22(6), 2942; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22062942 - 14 Mar 2021
Cited by 7 | Viewed by 2535
Abstract
In the last two decades, interest has grown significantly in the investigation of the role of trace amines and their receptors in mammalian physiology and pathology. Trace amine-associated receptor 9 (TAAR9) is one of the least studied members of this receptor family with [...] Read more.
In the last two decades, interest has grown significantly in the investigation of the role of trace amines and their receptors in mammalian physiology and pathology. Trace amine-associated receptor 9 (TAAR9) is one of the least studied members of this receptor family with unidentified endogenous ligands and an unknown role in the central nervous system and periphery. In this study, we generated two new TAAR9 knockout (TAAR9-KO) rat strains by CRISPR-Cas9 technology as in vivo models to evaluate the role of TAAR9 in mammalian physiology. In these mutant rats, we performed a comparative analysis of a number of hematological and biochemical parameters in the blood. Particularly, we carried out a complete blood count, erythrocyte osmotic fragility test, and screening of a panel of basic biochemical parameters. No significant alterations in any of the hematological and most biochemical parameters were found between mutant and WT rats. However, biochemical studies revealed a significant decrease in total and low-density lipoprotein cholesterol levels in the blood of both strains of TAAR9-KO rats. Such role of TAAR9 in cholesterol regulation not only brings a new understanding of mechanisms and biological pathways of lipid exchange but also provides a new potential drug target for disorders involving cholesterol-related pathology, such as atherosclerosis. Full article
(This article belongs to the Special Issue Orphan GPCRs: An Untapped Resource for Novel Drug Targets)
Show Figures

Figure 1

Back to TopTop